Prague Med. Rep. 2025, 126, 3-8

https://doi.org/10.14712/23362936.2025.1

Ormond’s Disease – 26 Years of Experience at One Centre

Miroslav Průcha1, Pavel Zdráhal2, Radek Kříž3, Alena Šnajdrová3, Luděk Voska4

1Department of Clinical Biochemistry, Haematology and Immunology, Hospital Na Homolce, Prague, Czech Republic
2Department of Vascular Surgery, Hospital Na Homolce, Prague, Czech Republic
3Department of Radiology, Hospital Na Homolce, Prague, Czech Republic
4Department of Clinical and Experimental Pathology, IKEM, Prague, Czech Republic

Received September 2, 2024
Accepted January 27, 2025

References

1. Boyeva, V., Alabsi, H., Seidman, M. A., Paterson, R., Kur, J., Chen, L. Y. C., Chang, S. D., Carruthers, M. (2020) Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol. 4, 40. <https://doi.org/10.1186/s41927-020-00140-9>
2. Cartery, C., Astudillo, L., Deelchand, A., Moskovitch, G., Sailler, L., Bossavy, J. P., Arlet, P. (2011) Abdominal infectious aortitis caused by Streptococcus pneumoniae: A case report and literature review. Ann. Vasc. Surg. 25, e9–e16. <https://doi.org/10.1016/j.avsg.2010.07.014>
3. Ebbo, M., Grados, A., Samson, M. (2017) Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 12(9), e0183844. <https://doi.org/10.1371/journal.pone.0183844>
4. Gianfreda, D., Superchi, E., Peyronel, F., Mazzariol, M., Vaglio, A. (2023) Chronic periaortitis: A clinical approach. Rev. Med. Interne 44(2), 79–84. <https://doi.org/10.1016/j.revmed.2022.11.009>
5. Hanazono, A., Sanpei, Y., Shimada, H., Yasuda, K., Takahashi, Y., Funasaka, H., Sagehashi, R., Hiroshima, Y., Nanjo, H., Sugawara, M. (2022) Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. eNeurologicalSci 29, 100428. <https://doi.org/10.1016/j.ensci.2022.100428>
6. Hao, M., Liu, M., Fan, G., Yang, X., Li, J. (2016) Diagnostic value of serum IgG4 for IgG4-related disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 95(21), e3785. <https://doi.org/10.1097/MD.0000000000003785>
7. Iaccarino, L., Talarico, R., Bozzalla-Cassione, E., Burmester, G. R., Culver, E. L., Doria, A., Ebbo, M., van Hagen, P. M., Hachulla, E., van Laar, J. A. M., Lanzillotta, M., Martinez-Valle, F., Montecucco, C., Monti, S., Nalli, C., Schleinitz, N., Tincani, A., Della-Torre, E., Alexander, T. (2022) Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. Clin. Exp. Rheumatol. 134(5), 71–80 (Suppl. 40). <https://doi.org/10.55563/clinexprheumatol/qq9qup>
8. Kermani, T. A., Crowson, C. S., Achenbach, S. J., Luthra, H. S. (2011) Idiopathic retroperitoneal fibrosis: A retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin. Proc. 86, 297–303. <https://doi.org/10.4065/mcp.2010.0663>
9. Khosroshahi, A., Carruthers, M. N., Stone, J. H., Shinagare, S., Sainani, N., Hasserjian, R. P., Deshpande, V. (2013) Rethinking Ormond’s disease: “Idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 92(2), 82–91. <https://doi.org/10.1097/MD.0b013e318289610f>
10. Laco, J., Podhola, M., Kamarádová, K., Novák, I., Dobeš, D., Broďák, M., Hácová, M., Ryška, A. (2013) Idiopathic vs. secondary retroperitoneal fibrosis: A clinicopathological study of 12 cases with emphasis to possible relationship to IgG4-related disease. Virchows Arch. 463, 721–730. <https://doi.org/10.1007/s00428-013-1480-7>
11. Parums, D. V. (1990) The spectrum of chronic periaortitis. Histopathology 16, 423–431. <https://doi.org/10.1111/j.1365-2559.1990.tb01541.x>
12. Peisen, F., Thaiss, W. M., Ekert, K., Horger, M., Amend, B., Bedke, J., Nikolaou, K., Kaufmann, S. (2020) Retroperitoneal fibrosis and its differential diagnoses: The role of radiological imaging. Rofo 192(10), 929–936.
13. Prucha, M., Sedivy, P., Stadler, P., Zdrahal, P., Prokopova, P., Voska, L., Sedlackova, L. (2019) Abdominal aortic aneurysm as an IgG4-related disease. Clin. Exp. Immunol. 197(3), 361–365. <https://doi.org/10.1111/cei.13307>
14. Sekar, N. (2010) Primary aortic infections and infected aneurysms. Ann. Vasc. Dis. 3(1), 24–27. <https://doi.org/10.3400/avd.ctiia09000>
15. Sica, A., Casale, B., Spada, A., Teresa Di Dato, M., Sagnelli, C., Calogero, A., Buonavolontà, P., Salzano, A., Martinelli, E., Saracco, E., Troiani, T., Anna Dodaro, C., Tammaro, D., Luisa De Rimini, M., Ciardiello, F., Papa, A. (2019) Differential diagnosis: Retroperitoneal fibrosis and oncological diseases. Open Med. (Wars.) 15, 22–26. <https://doi.org/10.1515/med-2020-0005>
16. Tanaka, T., Masumori, N. (2020) Current approach to diagnosis and management of retroperitoneal fibrosis. Int. J. Urol. 27(5), 387–394. <https://doi.org/10.1111/iju.14218>
17. Vaglio, A., Maritati, F. (2016) Idiopathic retroperitoneal fibrosis. J. Am. Soc. Nephrol. 27(7), 1880–1889. <https://doi.org/10.1681/ASN.2015101110>
18. van Bommel, E. F., Jansen, I., Hendriksz, T. R., Aarnoudse, A. L. (2009) Idiopathic retroperitoneal fibrosis: Prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88, 193–201. <https://doi.org/10.1097/MD.0b013e3181afc420>
19. Vianello, F., Romano Gargarella, L., Cinetto, F., Scarpa, R., Ceccato, J., Marcolongo, R. (2023) Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin. Exp. Rheumatol. 41(7), 1544–1547.
20. Wallwork, R., Wallace, Z., Perugino, C., Sharma, A., Stone, J. H. (2018) Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore) 97, e12631. <https://doi.org/10.1097/MD.0000000000012631>
21. Williams, G., Sarkar, B., Neilly, J. B., McKay, G. A. (2013) Spontaneous remission in a case of idiopathic retroperitoneal fibrosis. Scott. Med. J. 58(2), e7–e9. <https://doi.org/10.1177/0036933012474607>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive